keyword
MENU ▼
Read by QxMD icon Read
search

paclitaxel cancer

keyword
https://www.readbyqxmd.com/read/29909520/lapatinib-in-combination-with-paclitaxel-plays-synergistic-antitumor-effects-on-esophageal-squamous-cancer
#1
Xiao-Fang Guo, Sai-Sai Li, Xiao-Fei Zhu, Qiao-Hua Dou, Duan Liu
PURPOSE: Paclitaxel-based chemoradiotherapy was proven to be efficacious in treating patients with advanced esophageal cancer. However, the toxicity and the development of resistance limited its anticancer efficiency. The present study was to evaluate the antitumor effects of lapatinib, a dual tyrosine inhibitor of both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), combined with paclitaxel on the esophageal squamous cancer. METHODS: MTT assays were used to evaluate the effects of the combination of lapatinib and paclitaxel on the growth of esophageal squamous cancer cell lines (KYSE150, KYSE450, KYSE510 and TE-7)...
June 16, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29906554/flim-reveals-alternative-ev-mediated-cellular-up-take-pathways-of-paclitaxel
#2
REVIEW
H Saari, E Lisitsyna, K Rautaniemi, T Rojalin, L Niemi, O Nivaro, T Laaksonen, M Yliperttula, E Vuorimaa-Laukkanen
In response to physiological and artificial stimuli, cells generate nano-scale extracellular vesicles (EVs) by encapsulating biomolecules in plasma membrane-derived phospholipid envelopes. These vesicles are released to bodily fluids, hence acting as powerful endogenous mediators in intercellular signaling. EVs provide a compelling alternative for biomarker discovery and targeted drug delivery, but their kinetics and dynamics while interacting with living cells are poorly understood. Here we introduce a novel method, fluorescence lifetime imaging microscopy (FLIM) to investigate these interaction attributes...
June 12, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29905759/biomarker-assessment-of-the-cbcsg006-trial-a-randomized-phase-iii-trial-of-cisplatin-plus-gemcitabine-compared-with-paclitaxel-plus-gemcitabine-as-first-line-therapy-for-patients-with-metastatic-triple-negative-breast-cancer
#3
J Zhang, Y Lin, X J Sun, B Y Wang, Z H Wang, J F Luo, L P Wang, S Zhang, J Cao, Z H Tao, J Wu, Z M Shao, W T Yang, X C Hu
Background: CBCSG006 trial reported the superior efficacy of cisplatin plus gemcitabine (GP) regimen than paclitaxel plus gemcitabine (GT) regimen as first-line treatment of metastatic triple-negative breast cancer (mTNBC). This study focused on the updated survival data and the explorations of potential biomarkers for efficacy. Patients and methods: Germ-line mutations of homologous recombination (HR) panel, BRCA1/2 included, were evaluated in 55.9% (132/236) patients...
June 14, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29905606/the-effect-of-the-histone-deacetylase-inhibitor-suberoylanilide-hydroxamic-acid-and-paclitaxel-treatment-on-full-thickness-wound-healing-in-mice
#4
Joseph H Marcotte, Deviney A Rattigan, Robin F Irons, Kevin W Cahill, Ping Zhang, Shaohua Chang, Kiavash R Koko, John P Gaughan, Jeffrey P Carpenter, Spencer A Brown, Tulin Budak-Alpdogan
INTRODUCTION: Neoadjuvant chemotherapy prior to lumpectomy or mastectomy for breast cancer challenges wound healing. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, has been shown to work synergistically with paclitaxel in vitro and in preclinical studies. In addition, our laboratory has demonstrated that SAHA treatment decreases paclitaxel-associated stem cell toxicity, modulates inflammatory response, and promotes wound healing in injured fibroblast cells. Our goal was to determine if combined SAHA and paclitaxel treatment would improve wound healing in an in vivo full-thickness murine model, without altering antitumor effect...
June 13, 2018: Annals of Plastic Surgery
https://www.readbyqxmd.com/read/29903552/quality-adjusted-outcomes-stratified-by-response-in-patients-with-advanced-non-small-cell-lung-cancer-receiving-first-line-nab-paclitaxel-carboplatin-or-paclitaxel-carboplatin
#5
Vera Hirsh, Yin Wan, Fang-Ju Lin, Sandra Margunato-Debay, Teng Jin Ong, Marc Botteman, Corey Langer
BACKGROUND: First-line nab-paclitaxel/carboplatin was associated with a significantly improved overall response rate (primary endpoint) versus paclitaxel/carboplatin in a phase III trial of advanced non-small-cell lung cancer (NSCLC). We report the results of an analysis evaluating the correlation of response and the time to response with survival and quality-adjusted outcomes. PATIENTS AND METHODS: Using a landmark approach, progression-free survival (PFS), overall survival (OS), and quality-adjusted time without symptoms or toxicity (Q-TWiST) were compared between patients with a confirmed partial or complete response at or before 6 weeks (≤ 6-week responders) and those without (≤ 6-week nonresponders)...
May 7, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29903061/self-assembly-of-succinated-paclitaxel-into-supramolecular-hydrogel-for-local-cancer-chemotherapy
#6
Qianqian Song, Renshu Zhang, Lei Lei, Xingyi Li
In the present study, we reported the generation of a molecular hydrogel of succinated paclitaxel (PTX-SA) by a self-hydrolytic strategy for potential local cancer chemotherapy. Upon self-hydrolysis of the ester bond of PTX-SA in phosphate-buffered saline (pH = 7.4) for 24 h, a PTX-SA supramolecular hydrogel formed spontaneously with a minimal gelation concentration of 0.25 wt%. The formed PTX-SA supramolecular hydrogel displayed a filamentous nanostructure, the nanofibers of which were typically several micrometers in length with a diameter of 10-15 nm...
August 1, 2018: Journal of Biomedical Nanotechnology
https://www.readbyqxmd.com/read/29902349/nab-paclitaxel-interrupt-cancer-stromal-interaction-through-cxcl10-mediated-il-6-down-regulation-in-vitro
#7
Rui Feng, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Syuichi Iwahashi, Yu Saito, Mitsuo Shimada
Cancer-associated fibroblasts (CAFs), which derived from cancer tissues stroma, interact with cancer cells and play an important role in cancer initiation, growth and metastasis. Nab-paclitaxel (nab-PTX) is the 130nm albumin binding paclitaxel and recommended for many kinds of cancer chemotherapy. It has been reported that nab-PTX stromal disrupting effect during pancreatic cancer treatment. The aim of this study is to illustrate the role of nab-PTX in cancer cells and CAFs interaction. The cancer cells (Mia paca2 and Panc-1) were co-cultured with CAFs or treat with CAFs conditioned medium, then their migration and invasion ability, epithelial-mesenchymal transition (EMT) related markers expression and CXCL10 expression and secretion were detected...
June 14, 2018: Cancer Science
https://www.readbyqxmd.com/read/29902299/association-of-t-cell-receptor-repertoire-use-with-response-to-combined-trastuzumab-lapatinib-treatment-of-her2-positive-breast-cancer-secondary-analysis-of-the-neoaltto-randomized-clinical-trial
#8
Ryan L Powles, David Redmond, Christos Sotiriou, Sherene Loi, Debora Fumagalli, Paolo Nuciforo, Nadia Harbeck, Evandro de Azambuja, Severine Sarp, Serena Di Cosimo, Jens Huober, Jose Baselga, Martine Piccart-Gebhart, Olivier Elemento, Lajos Pusztai, Christos Hatzis
Importance: Dual anti-HER2 blockade increased the rate of pathologic complete response (pCR) in the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALTTO) trial, and high immune gene expression was associated with pCR in all treatment arms. So far, no marker has been identified that is specifically associated with the benefit from dual HER2 blockade. Objective: To examine if use of the T-cell β chain variable genes adds to the potential association of immune gene signatures with response to dual HER2 blockade...
June 14, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29901596/multiple-gastrointestinal-metastases-of-squamous-cell-lung-cancer-a-case-report
#9
Xinyu Li, Songhe Li, Zhiming Ma, Shutao Zhao, Xudong Wang, Dacheng Wen
RATIONALE: Gastrointestinal multiple metastases of lung cancer are extremely rare. The majority of gastrointestinal metastasis cases are diagnosed at a late stage and the prognosis is extremely poor. This report describes the clinical characteristics and outcomes of a patient with gastrointestinal multiple metastases from squamous-cell lung cancer, with special emphasis on the diagnosis and treatment of metastatic lung cancer. PATIENT CONCERNS: A 61-year-old man who presented with progressive abdominal distention was admitted to our hospital...
June 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29901126/synergistic-apoptotic-effects-of-silibinin-in-enhancing-paclitaxel-toxicity-in-human-gastric-cancer-cell-lines
#10
Yuanxin Zhang, Yakun Ge, Xie Ping, Ming Yu, Dawei Lou, Wei Shi
Gastric cancer (GC) is the 3rd leading cause of tumor‑associated mortality worldwide. The efficacy of paclitaxel, a frequently used GC chemotherapeutic agent, is hindered due to drug resistance, dose‑induced toxicity and adverse side effects. Silibinin, an active compound of a widely consumed dietary supplement, milk thistle extract, has recently been demonstrated to have strong antitumor efficacy in a human GC cell model. Thus, to enhance the efficacy of GC treatment, the present study evaluated whether silibinin exerted a synergistic therapeutic effect with paclitaxel...
June 5, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29900058/optimized-dendritic-cell-vaccination-induces-potent-cd8-t-cell-responses-and-anti-tumor-effects-in-transgenic-mouse-melanoma-models
#11
Mareike Grees, Adi Sharbi-Yunger, Christos Evangelou, Daniel Baumann, Gal Cafri, Esther Tzehoval, Stefan B Eichmüller, Rienk Offringa, Jochen Utikal, Lea Eisenbach, Viktor Umansky
Despite melanoma immunogenicity and remarkable therapeutic effects of negative immune checkpoint inhibitors, a significant fraction of patients does not respond to current treatments. This could be due to limitations in tumor immunogenicity and profound immunosuppression in the melanoma microenvironment. Moreover, insufficient tumor antigen processing and presentation by dendritic cells (DC) may hamper the development of tumor-specific T cells. Using two genetically engineered mouse melanoma models ( RET and BRAFV600E transgenic mice), in which checkpoint inhibitor therapy alone is not efficacious, we performed proof-of-concept studies with an improved, multivalent DC vaccination strategy based on our recently developed genetic mRNA cancer vaccines...
2018: Oncoimmunology
https://www.readbyqxmd.com/read/29899843/induction-of-apoptosis-and-suppression-of-tumor-growth-by-nur77-derived-bcl-2-converting-peptide-in-chemoresistant-lung-cancer-cells
#12
Martin C Pearce, John T Gamble, Prasad R Kopparapu, Edmond F O'Donnell, Monica J Mueller, Hyo Sang Jang, Julie A Greenwood, Arnold C Satterthwait, Robert L Tanguay, Xiao-Kun Zhang, Siva Kumar Kolluri
Resistance to chemotherapy is a major cause of treatment failure and poor overall survival in patients with lung cancer. Identification of molecular targets present in resistant cancer cells is essential for addressing therapeutic resistance and prolonging lung cancer patient survival. Members of the B-cell lymphoma 2 (Bcl-2) family of proteins are associated with chemotherapeutic resistance. In this study, we found that pro-survival protein Bcl-2 is upregulated in paclitaxel resistant cells, potentially contributing to chemotherapy resistance...
May 25, 2018: Oncotarget
https://www.readbyqxmd.com/read/29899826/synthetic-lethality-in-ccne1-amplified-high-grade-serous-ovarian-cancer-through-combined-inhibition-of-polo-like-kinase-1-and-microtubule-dynamics
#13
Sabrina Noack, Monika Raab, Yves Matthess, Mourad Sanhaji, Andrea Krämer, Balázs Győrffy, Lars Kaderali, Ahmed El-Balat, Sven Becker, Klaus Strebhardt
The taxanes are effective microtubule-stabilizing chemotherapy drugs that inhibit mitosis, induce apoptosis, and produce regression in a fraction of cancers that arise at many sites including the ovary. Novel therapeutic targets that augment taxane effects are needed to improve clinical chemotherapy response in CCNE1 -amplified high grade serous ovarian cancer (HGSOC) cells. In this study, we conducted an siRNA-based kinome screen to identify modulators of mitotic progression in CCNE1 -amplified HGSOC cells that may influence clinical paclitaxel response...
May 25, 2018: Oncotarget
https://www.readbyqxmd.com/read/29898269/metastatic-pancreatic-ductal-adenocarcinoma-diagnosis-and-treatment-with-a-view-to-the-future
#14
Adrian M J Pokorny, Venessa T Chin, Adnan M Nagrial, Desmond Yip, Lorraine A Chantrill
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a lethal disease with a poor 5-year survival. Systemic treatments can be used to control symptoms and prolong life. Cytotoxic chemotherapies are commonly administered, with combination treatments, such as fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) or nab-paclitaxel and gemcitabine showing the largest clinical benefits. Newer genomic classifications of PDAC may provide a rationale for targeted therapies or immunotherapies, although at present these remain largely experimental...
June 2018: Internal Medicine Journal
https://www.readbyqxmd.com/read/29897944/a-specific-expression-profile-of-lc3b-and-p62-is-associated-with-nonresponse-to-neoadjuvant-chemotherapy-in-esophageal-adenocarcinomas
#15
Olivia Adams, Félice A Janser, Bastian Dislich, Sabina Berezowska, Magali Humbert, Christian A Seiler, Dino Kroell, Julia Slotta-Huspenina, Marcus Feith, Katja Ott, Mario P Tschan, Rupert Langer
Paclitaxel is a powerful chemotherapeutic drug, used for the treatment of many cancer types, including esophageal adenocarcinomas (EAC). Autophagy is a lysosome-dependent degradation process maintaining cellular homeostasis. Defective autophagy has been implicated in cancer biology and therapy resistance. We aimed to assess the impact of autophagy on chemotherapy response in EAC, with a special focus on paclitaxel. Responsiveness of EAC cell lines, OE19, FLO-1, OE33 and SK-GT-4, to paclitaxel was assessed using Alamar Blue assays...
2018: PloS One
https://www.readbyqxmd.com/read/29896283/from-first-line-to-sequential-treatment-in-the-management-of-metastatic-pancreatic-cancer
#16
REVIEW
Andrés Muñoz Martín, Manuel Hidalgo, Rafael Alvarez, Virginia Arrazubi, Joaquina Martínez-Galán, Mercedes Salgado, Teresa Macarulla, Alfredo Carrato
The current management of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) is based on systemic chemotherapy. The results of the MPACT and PRODIGE clinical trials have demonstrated that the combination of nab-paclitaxel and gemcitabine (GEM) as well as FOLFIRINOX regimen result in improvement in overall survival when compared to GEM alone. Treatment guidelines now recommend either one of these two regimens as first line treatment for fit patients with mPDAC. Because no head-to-head comparison between the two regimens exists, the selection of one versus the other is based on clinical criteria...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29895863/pre-clinical-evaluation-of-ec1456-a-folate-tubulysin-anti-cancer-therapeutic
#17
Joseph A Reddy, Ryan Dorton, Alicia Bloomfield, Melissa Nelson, Christina Dircksen, Marilynn Vetzel, Paul Kleindl, Hari Santhapuram, Iontcho R Vlahov, Christopher P Leamon
EC1456 is a folate-tubulysin conjugate constructed with an all-D enantiomeric spacer/linker configuration. When tested against folate receptor (FR)-positive cells, EC1456 demonstrated dose-responsive activity with an approximate 1000-fold level of specificity. Treatment of nude mice bearing FR-positive human xenografts (as large as 800 mm3 ) with non-toxic doses of EC1456 led to cures in 100% of the mice. Combinations of low dose EC1456 with standard of care agents such as platins, taxanes, topotecan and bevacizumab, safely and significantly augmented the growth inhibitory effects of these commonly used agents...
June 12, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29891506/licofelone-enhances-the-efficacy-of-paclitaxel-in-ovarian-cancer-by-reversing-drug-resistance-and-tumor-stem-like-properties
#18
Jeff Hirst, Harsh B Pathak, Stephen Hyter, Ziyan Y Pessetto, Thuc Ly, Stefan Graw, Devin C Koestler, Adam J Krieg, Katherine F Roby, Andrew K Godwin
Drug development for front-line treatment of epithelial ovarian cancer (EOC) has been stagnant for almost three decades. Traditional cell culture methods for primary drug screening do not always accurately reflect clinical disease. To overcome this barrier, we grew a panel of EOC cell lines in three-dimensional (3D) cell cultures to form multicellular tumor spheroids (MCTS). We characterized these MCTS for molecular and cellular features of EOC and performed a comparative screen with cells grown using two-dimensional (2D) cell culture to identify previously unappreciated anti-cancer drugs...
June 11, 2018: Cancer Research
https://www.readbyqxmd.com/read/29890150/induction-chemo-radiation-50gy-followed-by-surgery-for-stage-iiia-n2-non-small-cell-lung-cancer
#19
Fumihiro Tanaka, Hiroyasu Yokomise, Toshinori Soejima, Hidetaka Uramoto, Takeharu Yamanaka, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Yasumasa Nishimura, Hiroshi Niwa, Morihito Okada, Tatsuo Nakagawa, Motohiro Yamashita
BACKGROUND: The optimal therapeutic strategy for potentially resectable clinical (c-) stage IIIA-N2 non-small cell lung cancer (NSCLC) remains controversial. This phase II multi-institutional study (WJOG5308L) was designed to evaluate the feasibility of induction chemotherapy with concurrent thoracic radiotherapy (50 Gy) followed by surgery and postoperative consolidation chemotherapy in IIIA-N2 NSCLC. METHODS: Patients with resectable c-stage IIIA-N2 were eligible, and pathological confirmation of N2 disease was mandatory...
June 8, 2018: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/29888659/-paclitaxel-containing-chemotherapeutic-regimens-in-first-line-and-reintroduced-palliative-treatment-of-metastatic-cervical-cancer
#20
Tamás Kullmann, István Sipőcz, Kofi Agyemang-Prempeh, Orsolya Barna, Tamás Pintér
INTRODUCTION: The paclitaxel-carboplatin doublet is an alternative choice in the first line treatment of metastatic or recurrent cervical cancer according to international guidelines. METHOD: The history of seven patients treated with paclitaxel-platinum in the last three years in the Petz Aladár Hospital is reported. A case report, supporting the efficacy of the combination in emergency and in reintroduced settings is presented as well. RESULTS: The average progression-free survival was 10 months...
June 2018: Orvosi Hetilap
keyword
keyword
68450
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"